Targacept to Present at the Stifel Nicolaus 2012 Healthcare Conference
WINSTON-SALEM, N.C.--(BUSINESS WIRE)-- Targacept, Inc. (TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that Alan A. Musso, Senior Vice President, Finance and Administration and Chief Financial Officer, is scheduled to present at the Stifel Nicolaus 2012 Healthcare Conference at Four Seasons Hotel Boston on Wednesday, September 5, 2012 at 1:30 p.m. Eastern Time.
The presentation will be webcast and accessible from the Investor Relations page of Targacepts website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Investor Calendar section of the Investor Relations page of Targacepts website for at least two weeks following the event.
Targacept is developing a diverse pipeline of innovative NNR TherapeuticsTM for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacepts clinical pipeline includes Phase 2 product candidates representing first-in-class opportunities. Targacept leverages its scientific leadership and proprietary drug discovery platform PentadTM to fuel its pipeline and attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.
Building Health, Restoring Independence®
Alan Musso, 336-480-2186
SVP, Finance and Administration and CFO
Michelle Linn, 508-362-3087
Source: Targacept, Inc.Copyright Business Wire 2012